Compliance research

IEEE Std 11073-10207-2017 [Including Cor 1-2025] — FDA recognition transition and report handoff

FDA’s acquired supplementary sheets explicitly connect 13-106 to 13-157 and state declaration-acceptance date(s) for the replaced recognition: recognition 13-106: 2028-07-02. Compare the exact edition and recognition limitations with your reports before agreeing the submission evidence or further work.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Exact FDA recognition records

Compare the edition and the recognized portion

Read these columns together. A complete recognition is not a device-specific testing instruction. The limitations are the FDA’s public metadata; the licensed standard itself is not reproduced.

Recognition / editionPublic recognition limitationsDeclaration transition context
FDA 13-106
IEEE Std 11073-10207-2017; ISO IEEE 11073-10207-2019

Health informatics - Point-of-care medical device communication Part 10207: Domain Information and Service Model for Service-Oriented Point-of-Care Medical Device Communication; Health informatics - Point-of-care medical device communication Part 10207: Domain information and service model for service-oriented point-of-care medical device communication

Complete

Complete standard

[2] [4] [6]
Exported transition expiration: 07/02/2028
FDA 13-157
IEEE Std 11073-10207-2017 [Including Cor 1-2025]

Health informatics - Point-of-care medical device communication Part 10207: Domain Information and Service Model for Service-Oriented Point-of-Care Medical Device Communication [Including Corrigendum 1 (2025)]

Complete

Complete standard

[1] [3]
No expiration date is stated in this acquired export row. That is not a guarantee of indefinite recognition.

What FDA’s transition statement says

Recognition 13-106 → 13-157

FDA recognition of IEEE Std 11073-10207-2017 [Rec# 13-106] will be superseded by recognition of IEEE Std 11073-10207-2017/Cor 1-2025 [Rec# 13-157]. FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 13-106] until July 2, 2028. After this transition period, declarations of conformity to [Rec# 13-106] will not be accepted.

Exact statements were reconciled on both acquired sheets and against the old recognition’s exported date. [5] [7]

FDA public recognition metadata describes use of declarations of conformity in support of premarket submissions. A recognition transition is not a universal retesting deadline, a product ban, or proof that this standard applies to your device. The technical differences between licensed editions, adequacy of existing reports, buyer-specific route and final test scope remain incomplete. The comparison below does not reproduce the standard or establish FDA approval.

Method: Exact directed old-to-new statements are reconciled across both acquired sheets and the old export date. No name-similarity mapping or technical-clause inference.

Build your edition-to-report handoff matrix

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Which edition is actually in your evidence?

    Reconcile each report and declaration against IEEE Std 11073-10207-2017 [Including Cor 1-2025] and the replaced designation(s) IEEE Std 11073-10207-2017; ISO IEEE 11073-10207-2019. Record amendments and the exact report/device revision. A similar standard number is not an edition match.

    Useful evidence: Report cover, method/edition references, amendments, declarations and device/configuration revision.

  2. Does the declaration cover the recognized portion?

    Use the complete FDA public limitation text in the comparison table. Map each listed exclusion, where present, to the relevant report sections and obtain a reasoned evidence assessment. Complete recognition still does not determine device applicability.

    Useful evidence: Recognition-to-report coverage matrix, excluded-clause assessment and the licensed edition used by your specialist.

  3. How does the recorded transition affect your submission plan?

    Record planned declaration/submission dates against the FDA sheet’s acceptance date(s): recognition 13-106: 2028-07-02. This concerns declarations supporting premarket submissions to the replaced recognition; do not treat it as a blanket deadline to retest or stop selling.

    Useful evidence: Submission plan, intended declaration references, dated recognition-sheet check and rationale for the chosen evidence route.

  4. What changed beyond the designation?

    Ask the specialist to assess the actual licensed edition/amendment differences for your design, materials, software and use environment. Separate a documented evidence gap from a changed title. This metadata comparison does not establish which tests changed or must be repeated.

    Useful evidence: Edition gap assessment tied to the device and existing evidence, with a bridging rationale and unresolved inputs.

  5. What should the quote include?

    Request a report/recognition reconciliation and a justified gap assessment first. Separate any proposed additional evaluation or testing, samples, methods, deliverables and exclusions; agree them only after applicability and existing evidence are assessed.

    Useful evidence: A scoped evidence-assessment quote; separately identified conditional work and report ownership.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA — recognition metadata exported through the official search form ↗

Version not stated by the source · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 94ccf56dc846c7f6d78d6ad77dc6e87d1803ac3612af01d6894949e34c4a78d8

  • [1] CSV row 74 · record 1ec2889423e987d81acfef5ea5fd0c7bebc4306f64de47d29a253c4b44115376
  • [2] CSV row 1225 · record 9d0134da349e8a0794e2613874b15ba515b3c2d211f09c65cdf6ad9908efe6ae
  • [6] CSV row 1224 · record c1a093166516bfccf791f826b9626ba02d65d0ca8c81806a65b449b808107b54

FDA — recognised standards metadata ↗

Version not stated by the source · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 7e04590e9c7494b90a0bdef1a60acb9ebc7ce6f4f2a5759e2421bbf85e93a5c4

  • [3] HTML tr 18 / Extent of Recognition / nested table · record abe979994f401294b5be13a259f2f515e156238e3707a00616452ec2cb39b2be
  • [7] HTML tr 22 / Transition Period / nested table · record f03ce2455b0f3548c7c4039aef843527658e57c174214b3f328d73084930b0b1

FDA — recognised standards metadata ↗

Version not stated by the source · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 6a3a9cee98368d5bbec47ce539bb3df9cc653a1f89ccafc622093b29c3a77263

  • [4] HTML tr 20 / Extent of Recognition / nested table · record b39d4f836f6e05955dbd090aa625cb1b0013479b972d2a9544a52d0466ab4aa1
  • [5] HTML tr 24 / Transition Period / nested table · record b66d42d109ad64a4ffdbe764271c4efbbe3044b2838d14f8352388a167304f1c

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services